Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Country / region: Germany Clear all

527 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20023
20037
20047
20056
200616
200732
200833
200939
201037
201141
201224
201329
201440
201523
201630
201716
201813
201927
202016
202115
202217
202314
202416
202517
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed418
Unknown status31
Terminated30
Recruiting25
Active, not recruiting12
Withdrawn8
Not yet recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
GlaxoSmithKline90
AstraZeneca69
Boehringer Ingelheim68
Schön Klinik Berchtesgadener Land34
Novartis Pharmaceuticals32
Novartis15
Chiesi Farmaceutici S.p.A.10
Sanofi10
Institut für Pneumologie Hagen Ambrock eV9
RWTH Aachen University9

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive527
Asthma34
Emphysema34
Lung Diseases21
Bronchitis, Chronic18
Heart Failure12
Pulmonary Emphysema11
Lung Diseases, Interstitial9
Lung Diseases, Obstructive9
Respiratory Tract Diseases9

Trials

Showing 1 to 25 of 527. Each trial links to its page on Pharma Observatory.

427 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.